India is experiencing a quiet but powerful transformation in biotechnology, driven by a new generation of scientific entrepreneurs who are reshaping healthcare access and affordability.
Homegrown Breakthroughs Led by Start-Ups
Arjun Arunachalam’s Voxel Grids Innovations in Bengaluru has developed India’s first indigenously built MRI scanner—lighter, more energy-efficient, and far cheaper than imported options. Already in use in hospitals in Mumbai and Assam, it is helping expand advanced diagnostics to millions who lacked access.
Likewise, Jatin Vimal of Levim Lifetech in Chennai has produced India’s first biosimilar Liraglutide for Type 2 diabetes. Despite the complexity of engineering biologics, his start-up now offers the drug at one-third the cost of imported versions and reached break-even within a year.
Beyond these successes, several Indian ventures are developing new antibiotics and pioneering vaccines for dengue, chikungunya, malaria, and even Hepatitis E. Indigenous cell therapies for acute lymphoma are also emerging, along with innovations in implants, endoscopes, and stem cell treatments.
As per the World Bank Group, these breakthroughs exemplify India’s rapidly strengthening biopharma ecosystem.
National Biopharma Mission: A Catalyst for Innovation
All these achievements have been supported by the National Biopharma Mission (NBM), funded through the World Bank–backed Innovate in India for Inclusiveness (i3) Project. According to Dr. Jitendra Kumar of BIRAC, the Mission links “discovery with delivery,” enabling India to advance affordable, high-impact therapies.
A major priority of the Mission has been strengthening collaboration among industry, academia, and government. Through Scientific Advisory Groups, shared research agendas now guide public health–oriented innovation.
Building India’s Biotech Start-Up Ecosystem
Since 2014, nearly 10,000 bio-based start-ups have emerged, supported directly or indirectly by NBM. The Mission has helped establish about 100 incubation centers and 25 specialized R&D and manufacturing facilities in hubs such as C-CAMP Bengaluru, Venture Center Pune, AMTZ Visakhapatnam, and IIT Kanpur. These centers provide shared labs, mentorship, regulatory guidance, and early-stage funding.
Arjun Arunachalam credits the Mission’s ₹12.4 crore support for enabling him to move from concept to production.
Strengthening IP, Skills, and Clinical Capacity
To protect innovation, the Mission has trained over 7,000 people—45% women—in global and national IP regulations. Seven Regional Technology Transfer Offices now manage more than 850 IP filings and nearly 120 technology transfers.
To accelerate biopharma product development, the Mission has also built 30 hospital trial sites and 10 field sites, maintaining a volunteer pool of around 800,000 people. More than 100 clinical trials have been supported. Jatin Vimal notes that NBM funding covered 85% of his clinical trial costs and provided valuable regulatory and technical guidance.
Advancing Vaccines for India and the World
A landmark achievement is the support for ZyCoV-D, the world’s first DNA-based COVID-19 vaccine developed by Zydus Cadila. The Mission is also backing Bharat Biotech’s chikungunya vaccine, which is nearing launch and expected to serve markets in India, Africa, Southeast Asia, and Latin America.
A Blueprint for India’s Biopharma Future
Entrepreneurs consistently highlight India’s deep talent pool, strong work ethic, and capacity to innovate when given the right environment. As Dr. Raj K. Shirumalla notes, India already leads in generic medicines and vaccines and now has the potential to become a global biopharma powerhouse—delivering not just volume but high-value scientific innovation.
With continued investment, supportive regulations, and strong public–private partnerships, India is poised to scale its biopharma momentum and contribute significantly to global health.